Avery Dennison (AVY) Confirms New Adhesive Provides Antimicrobial Rfficacy
Tweet
Share
E-mailGet Alerts AVY Hot Sheet
Join SI Premium – FREE
Tests conducted by an independent laboratory for Avery Dennison Medical Solutions, a division of Avery Dennison Corporation (NYSE: AVY) and a global leader in adhesive technologies for medical applications, confirm that the new Avery Dennison Medical Solutions Chlorhexidine Gluconate (CHG) adhesive delivery system (ADS) provides antimicrobial efficacy across a broad range of bacteria and yeast. These data demonstrate that the challenge of incorporating CHG within a solvent acrylic adhesive has been successfully addressed.
These preliminary tests show that the new CHG ADS may be appropriate for applications where the spread of infection is a concern and moisture management and transparency are required, such as the securement of IV catheters, surgical incision films and post-op dressings.
These preliminary tests show that the new CHG ADS may be appropriate for applications where the spread of infection is a concern and moisture management and transparency are required, such as the securement of IV catheters, surgical incision films and post-op dressings.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
- CoVolt Power files for proposed IPO
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
